Targeting 20-HETE producing enzymes in cancer - Rationale, pharmacology, and clinical potential

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 243-255

  Alexanian, Anna ^a   Sorokin, Andrey ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

20 hydroxyeicosatetraenoic acid; CYP4A; CYP4F; Eicosanoids; HET0016

Indexed keywords

20 HYDROXYEICOSA DIENOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 4A11; CYTOCHROME P450 4A22; CYTOCHROME P450 4F2; CYTOCHROME P450 4F3; HET 0016; N (20 HYDROXYEICOSA DIENYL)GLYCINE; N HYDROXY N' (4 BUTYL 2 METHYLPHENYL)FORMAMIDINE; UNCLASSIFIED DRUG; WIT 002; WIT 003;

CANCER GROWTH; CANCER THERAPY; CELL PROLIFERATION; DRUG TARGETING; ENZYME IMMUNOASSAY; FATTY ACID SYNTHESIS; HUMAN; LIQUID CHROMATOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MASS FRAGMENTOGRAPHY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVIEW; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84875437791     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S31586     Document Type: Review

References (92)

1. Guo AM, Arbab AS, Falck JR, et al. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther. 2007;321(1):18-27.
2. Stec DE, Gannon KP, Beaird JS, Drummond HA. 20-hydroxyeicosatetraenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem. 2007;19(1-4):121-128.
3. Lin F, Rios A, Falck JR, Belosludtsev Y, Schwartzman ML. 20-hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule. Am J Physiol. 1995;269(6 Pt 2): F806-F816.
4. O'Donnell VB, Maskrey B, Taylor GW. Eicosanoids: generation and detection in mammalian cells. Methods Mol Biol. 2009;462:5-23.
5. Imig JD. Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol. 2000;279(6):F965-F981.
6. Chatziantoniou C, Arendshorst WJ. Renal vascular reactivity to vasodilator prostaglandins in genetically hypertensive rats. Am J Physiol. 1992;262(1 Pt 2):F124-F130.
7. Wang D, DuBois RN. Prostaglandins and cancer. Gut. 2006;55(1): 115-122.
8. Wang D, DuBois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181-193.
9. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122(5):518-523.
10. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol. 2004;31(1 Suppl 3):64-73.
11. McLemore TL, Hubbard WC, Litterst CL, et al. Profiles of prostaglandin biosynthesis in normal lung and tumor tissue from lung cancer patients. Cancer Res. 1988;48(11):3140-3147.
12. Sorokin A. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des. 2004;10(6): 647-657.
13. Patel VA, Dunn MJ, Sorokin A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem. 2002;277(41):38915-38920.
14. Myung SJ, Rerko RM, Yan M, et al. 15-hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A. 2006;103(32):12098-12102.
15. Nakanishi M, Montrose DC, Clark P, et al. Genetic deletion of mPGES-1suppresses intestinal tumorigenesis. Cancer Res. 2008;68(9): 3251-3259.
16. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003;278(37):35451-35457.
17. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8(3):289-293.
18. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001;276(21):18075-18081.
19. Wang D, Wang H, Shi Q, et al. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 2004;6(3): 285-295.
20. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2in human colon cancer cells. Cancer Res. 1998;58(2):362-366.
21. Poligone B, Baldwin AS. Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem. 2001;276(42): 38658-38664.
22. Fosslien E. Review: molecular pathology of cyclooxygenase-2in cancer-induced angiogenesis. Ann Clin Lab Sci. 2001;31(4):325-348.
23. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19(1-2):19-27.
24. Takaku K, Sonoshita M, Sasaki N, et al. Suppression of intestinal polyposis in Apc(delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem. 2000; 275(44):34013-34016.
25. Trompezinski S, Pernet I, Schmitt D, Viac J. UV radiation and prostaglandin E2 up-regulate vascular endothelial growth factor (VEGF) in cultured human fibroblasts. Inflamm Res. 2001;50(8):422-427.
26. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H, Tarnawski AS. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun. 2001;286(5): 923-928.
27. Pradono P, Tazawa R, Maemondo M, et al. Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res. 2002;62(1):63-66.
28. Il Lee S, Zuo X, Shureiqi I. 15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in? Cancer Metastasis Rev. 2011; 30(3-4):481-491.
29. Gao X, Grignon DJ, Chbihi T, et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology. 1995;46(2):227-237.
30. Larré S, Tran N, Fan C, et al. PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat. 2008;87(1-4): 14-19.
31. Dreyling KW, Hoppe U, Peskar BA, Morgenroth K, Kozuschek W, Peskar BM. Leukotriene synthesis by human gastrointestinal tissues. Biochim Biophys Acta. 1986;878(2):184-193.
32. Hennig R, Ding XZ, Tong WG, et al. 5-lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am J Pathol. 2002;161(2):421-428.
33. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A. Blockade of leukotriene B4signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci. 2007; 103(1):24-32.
34. Kandouz M, Nie D, Pidgeon GP, Krishnamoorthy S, Maddipati KR, Honn KV. Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells. Prostaglandins Other Lipid Mediat. 2003;71(3-4): 189-204.
35. Nie D, Krishnamoorthy S, Jin R, et al. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem. 2006;281(27):18601-18609.
36. McCabe NP, Selman SH, Jankun J. Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase. Prostate. 2006;66(7):779-787.
37. Tang DG, Grossi IM, Chen YQ, Diglio CA, Honn KV. 12(S)-HETE promotes tumor-cell adhesion by increasing surface expression of alpha V beta 3integrins on endothelial cells. Int J Cancer. 1993;54(1):102-111.
38. Panigrahy D, Kaipainen A, Greene ER, Huang S. Cytochrome P450-derived eicosanoids: the neglected pathway in cancer. Cancer Metastasis Rev. 2010;29(4):723-735.
39. Roman RJ. P-450metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82(1):131-185.
40. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res. 2000;41(2):163-181.
41. Wang D, DuBois RN. Measurement of eicosanoids in cancer tissues. Methods Enzymol. 2007;433:27-50.
42. Powell PK, Wolf I, Jin R, Lasker JM. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther. 1998;285(3):1327-1336.
43. Bellamine A, Wang Y, Waterman MR, et al. Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Arch Biochem Biophys. 2003;409(1):221-227.
44. Christmas P, Jones JP, Patten CJ, et al. Alternative splicing determines the function of CYP4F3 by switching substrate specificity. J Biol Chem. 2001;276(41):38166-38172.
45. Yu W, Chai H, Li Y, et al. Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 2012;264(1):73-83.
46. Muller DN, Schmidt C, Barbosa-Sicard E, et al. Mouse Cyp4a isoforms: enzymatic properties, gender-and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation. Biochem J. 2007;403(1):109-118.
47. Yamaguchi Y, Kirita S, Hasegawa H, et al. Contribution of CYP4A8 to the formation of 20-hydroxyeicosatetraenoic acid from arachidonic acid in rat kidney. Drug Metab Pharmacokinet. 2002;17(2):109-116.
48. Nakagawa K, Holla VR, Wei Y, et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10gene and kidney epithelial sodium channel. J Clin Invest. 2006;116(6):1696-1702.
49. Escalante B, Sessa WC, Falck JR, Yadagiri P, Schwartzman ML. Vasoactivity of 20-hydroxyeicosatetraenoic acid is dependent on metabolism by cyclooxygenase. J Pharmacol Exp Ther. 1989;248(1): 229-232.
50. Harder DR, Narayanan J, Gebremedhin D. Pressure-induced myogenic tone and role of 20-HETE in mediating autoregulation of cerebral blood flow. Am J Physiol Heart Circ Physiol. 2011;300(5):H1557-H1565.
51. Williams JM, Sarkis A, Lopez B, Ryan RP, Flasch AK, Roman RJ. Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension. 2007;49(3):687-694.
52. Williams JM, Murphy S, Burke M, Roman RJ. 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol. 2010;56(4):336-344.
53. Quigley R, Baum M, Reddy KM, Griener JC, Falck JR. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol Renal Physiol. 2000;278(6):F949-F953.
54. Wang S, Meng F, Xu J, Gu Y. Effects of lipids on ENaC activity in cultured mouse cortical collecting duct cells. J Membr Biol. 2009;227(2):77-85.
55. Pavlov TS, Ilatovskaya DV, Levchenko V, Mattson DL, Roman RJ, Staruschenko A. Effects of cytochrome P-450metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am J Physiol Renal Physiol. 2011;301(3):F672-F681.
56. Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension. 2003;42(4): 669-673.
57. Chen L, Ackerman R, Guo AM. 20-HETE in neovascularization. Prostaglandins Other Lipid Mediat. 2012;98(3-4):63-68.
58. Amaral SL, Maier KG, Schippers DN, Roman RJ, Greene AS. CYP4A metabolites of arachidonic acid and VEGF are mediators of skeletal muscle angiogenesis. Am J Physiol Heart Circ Physiol. 2003;284(5): H1528-H1535.
59. Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res. 2012;114:237-267.
60. Ishizuka T, Cheng J, Singh H, et al. 20-hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther. 2008;324(1):103-110.
61. Zeng Q, Han Y, Bao Y, et al. 20-HETE increases NADPH oxidase-derived ROS production and stimulates the L-type Ca2+ channel via a PKC-dependent mechanism in cardiomyocytes. Am J Physiol Heart Circ Physiol. 2010;299(4):H1109-H1117.
62. Akbulut T, Regner KR, Roman RJ, Avner ED, Falck JR, Park F. 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR-and c-Src-dependent mechanism. Am J Physiol Renal Physiol. 2009;297(3):F662-F670.
63. Alexanian A, Miller B, Roman RJ, Sorokin A. 20-HETE-producing enzymes are up-regulated in human cancers. Cancer Genomics Proteomics. 2012;9(4):163-169.
64. Lai G, Wu J, Liu X, Zhao Y. 20-HETE induces hyperglycemia through the cAMP/PKA-PhK-GP pathway. Mol Endocrinol. 2012;26(11): 1907-1916.
65. Guo M, Roman RJ, Fenstermacher JD, et al. 9L gliosarcoma cell proliferation and tumor growth in rats are suppressed by N-hydroxy-N′-(4-butyl-2-methylphenol) formamidine (HET0016), a selective inhibitor of CYP4A. J Pharmacol Exp Ther. 2006;317(1):97-108.
66. Alexanian A, Rufanova VA, Miller B, Flasch A, Roman RJ, Sorokin A. Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth. Anticancer Res. 2009;29(10):3819-3824.
67. Miyata N, Taniguchi K, Seki T, et al. HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol. 2001;133(3):325-329.
68. Sato M, Ishii T, Kobayashi-Matsunaga Y, et al. Discovery of a N′-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett. 2001;11(23):2993-2995.
69. Yu M, Cambj-Sapunar L, Kehl F, et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004;486(3): 297-306.
70. Qin X, Kwansa H, Bucci E, Roman RJ, Koehler RC. Role of 20-HETE in the pial arteriolar constrictor response to decreased hematocrit after exchange transfusion of cell-free polymeric hemoglobin. J Appl Physiol. 2006;100(1):336-342.
71. Stec DE, Gannon KP, Beaird JS, Drummond HA. 20-hydroxyeicosatetraenoic acid (20-HETE) stimulates migration of vascular smooth muscle cells. Cell Physiol Biochem. 2007;19(1-4):121-128.
72. Tunctan B, Korkmaz B, Buharalioglu CK, et al. A 20-hydroxyeicosatetraenoic acid agonist, N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine, opposes the fall in blood pressure and vascular reactivity in endotoxin-treated rats. Shock. 2008;30(3):329-335.
73. Regner KR, Zuk A, Van Why SK, et al. Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury. Kidney Int. 2009;75(5):511-517.
74. Park F, Sweeney WE, Jia G, Roman RJ, Avner ED. 20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease. J Am Soc Nephrol. 2008;208(10):1929-1939.
75. Nithipatikom K, Isbell MA, See WA, Campbell WB. Elevated 12-and 20-hydroxyeicosatetraenoic acid in urine of patients with prostatic diseases. Cancer Lett. 2006;233(2):219-225.
76. Jacobs VL, Valdes PA, Hickey WF, De Leo JA. Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro. 2011;3(3):e00063.
77. Guo M, Roman RJ, Falck JR, Edwards PA, Scicli AG. Human U251glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N′-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A. J Pharmacol Exp Ther. 2005;315(2):526-533.
78. Chen P, Guo M, Wygle D, et al. Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol. 2005;166(2):615-624.
79. Guo AM, Sheng J, Scicli GM, et al. Expression of CYP4A1in U251 human glioma cell induces hyperproliferative phenotype in vitro and rapidly growing tumors in vivo. J Pharmacol Exp Ther. 2008;327(1): 10-19.
80. Yu W, Chen L, Yang YQ, et al. Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9in non-small cell lung cancer. Cancer Chemother Pharmacol. 2011;68(3):619-629.
81. Weiss RH, Lin PY. Kidney cancer: identification of novel targets for therapy. Kidney Int. 2006;69(2):224-232.
82. Wu CC, Liu Y, Chen J, et al. CYP4F isoform expression and 20-HETE synthesis in prostate cancer cells are regulated by androgen and contribute to growth [abstract]. Cancer Res. 2012;72(8 Suppl 1): LB-160.
83. Arun B, Goss P. The role of COX-2inhibition in breast cancer treatment and prevention. Semin Oncol. 2004;31(2 Suppl 7):22-29.
84. Badawi AF. The role of prostaglandin synthesis in prostate cancer. BJU Int. 2000;85(4):451-462.
85. Gupta RA, DuBois RN. Translational studies on Cox-2inhibitors in the prevention and treatment of colon cancer. Ann N Y Acad Sci. 2000; 910:196-204.
86. Myers CE, Ghosh J. Lipoxygenase inhibition in prostate cancer. Eur Urol. 1999;35(5-6):395-398.
87. Sorokin A. Eicosanoids and resistance of cancer cells to chemotherapeutic agents. In: Bonavida B, editor. Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. Los Angeles, CA: Humana Press; 2008:133-156.
88. Khan M, Fraser A. Cox-2inhibitors and the risk of cardiovascular thrombotic events. Ir Med J. 2012;105(4):119-121.
89. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res. 2013;191:67-93.
90. Gibson GG. Comparative aspects of the mammalian cytochrome P450 IV gene family. Xenobiotica. 1989;19(10):1123-1148.
91. McGiff JC, Carroll MA. Cytochrome P450-dependent arachidonate metabolites, renal function and blood pressure regulation. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:675-682.
92. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res. 2005;41(4): 175-193.